Salvage therapy with pegylated liposomial doxorubicin-based regimen in relapsed/refractory multiple myeloma: comments to the article by Romano et al.

Cerchione Claudio; Lucignano Mariano; Pane Fabrizio; Catalano Lucio

首页> 外文期刊>European Journal of Haematology >Salvage therapy with pegylated liposomial doxorubicin-based regimen in relapsed/refractory multiple myeloma: comments to the article by Romano et al.

【24h】

Salvage therapy with pegylated liposomial doxorubicin-based regimen in relapsed/refractory multiple myeloma: comments to the article by Romano et al.

机译：聚乙二醇化脂质体阿霉素治疗复发/难治性多发性骨髓瘤的挽救疗法：Romano等对本文的评论。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Haematology》 |2016年第5期|共1页
作者
Cerchione Claudio; Lucignano Mariano; Pane Fabrizio; Catalano Lucio;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Salvage therapy with pegylated liposomial doxorubicin-based regimen in relapsed/refractory multiple myeloma: comments to the article by Romano et al. [J] . Cerchione Claudio, Lucignano Mariano, Pane Fabrizio, European Journal of Haematology . 2016,第5期

机译：聚乙二醇化脂质体阿霉素治疗复发/难治性多发性骨髓瘤的挽救疗法：Romano等对本文的评论。
2. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. [J] . Baz R, Walker E, Karam MA, Annals of oncology: official journal of the European Society for Medical Oncology . 2006,第12期

机译：Lenalidomide和Pegymated脂质体DOXORUBICIN的复发或难治多骨髓瘤的化学疗法：安全性和疗效。
3. Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. [J] . Chanan Khan A, Miller KC, Musial L Leukemia and lymphoma . 2009,第7期

机译：硼替佐米联合聚乙二醇化脂质体阿霉素和沙利度胺对复发或难治性多发性骨髓瘤患者是一种有效的类固醇独立治疗方案：II期临床试验的结果。
4. Durability of Response with Thalidomide Therapy for Relapsed Multiple Myeloma [C] . B. Myers, S.G. Jones, G. Do I an European Haematology Association . 2002

机译：耐久性耐久性与多发性骨髓瘤复发疗法
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma [O] . Edward A Stadtmauer, Donna M Weber, Ruben Niesvizky, -1

机译：来那度胺在首次复发时与地塞米松联合使用与后来用于复发或难治性多发性骨髓瘤的挽救疗法相比
7. Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma [O] . Luciano J. Costa, Heather J. Landau, Saurabh Chhabra, 2018

机译：Carfilzomib的第1/2阶段试验加上高剂量Melphalan制备方案，用于拯救自体造血细胞移植，然后在复发/难治性多发性骨髓瘤患者中进行维持肠道

Salvage therapy with pegylated liposomial doxorubicin-based regimen in relapsed/refractory multiple myeloma: comments to the article by Romano et al.

著录项

相似文献

相关主题

期刊订阅